Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Total Liabilities (2016 - 2025)

Altimmune (ALT) has disclosed Total Liabilities for 16 consecutive years, with $32.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities rose 126.73% to $32.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $32.8 million, a 126.73% increase, with the full-year FY2024 number at $15.8 million, down 4.49% from a year prior.
  • Total Liabilities was $32.8 million for Q3 2025 at Altimmune, up from $29.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $32.8 million in Q3 2025 to a low of $14.5 million in Q3 2024.
  • A 5-year average of $19.5 million and a median of $17.8 million in 2021 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: plummeted 30.58% in 2021, then skyrocketed 126.73% in 2025.
  • Altimmune's Total Liabilities stood at $19.7 million in 2021, then increased by 9.66% to $21.6 million in 2022, then decreased by 23.55% to $16.5 million in 2023, then dropped by 4.49% to $15.8 million in 2024, then skyrocketed by 107.91% to $32.8 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Total Liabilities are $32.8 million (Q3 2025), $29.0 million (Q2 2025), and $15.1 million (Q1 2025).